Select Subscriptions, and then under Product Name, select the subscription you purchased to view billing information.

Select the App launcher towards the upper-left of the window, and then select Admin. Step 3 - See what’s included in your subscriptionĪfter you purchase a business plan, it's a good idea to review what's in it and to review your account information. When you sign up for a subscription, you specify an alternate email address where you'll get emails from Microsoft that include links to sign into your Microsoft 365 business account.

Go to and sign in with your business username and password. Visit the Microsoft 365 for business website and choose a plan that meets the needs of your business. If you haven’t already purchased a subscription, the first step in getting started with Microsoft 365 is to sign up for a business plan. Step 1 - Sign up for a Microsoft 365 business plan Outlook Therapeutics also intends to commence additional clinical trials for ONS-5010 in DME and BRVO following approval for wet AMD.Here are some key steps to getting started with Microsoft 365 small business. If the BLA is approved, it is expected to result in 12 years of regulatory exclusivity for ONS-5010 as the first and only ophthalmic formulation of bevacizumab approved by the FDA to treat wet AMD. With the registration clinical trials completed, Outlook Therapeutics submitted a new BLA under the Public Health Service Act (PHSA) 351(a) regulatory pathway. The submission is supported by Outlook Therapeutics’ wet AMD registration clinical program, which consists of three clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE. The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023. Food and Drug Administration accepted Outlook Therapeutics’ Biologics License Application (BLA) filing for review for ONS-5010 to treat wet AMD on October 27, 2022. Bevacizumab is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody (or mAb) that inhibits VEGF and associated angiogenic activity. ONS-5010/ LYTENAVA™ (bevacizumab-vikg) is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet AMD and other retinal diseases.

Outlook business